



(86) Date de dépôt PCT/PCT Filing Date: 1997/11/25
(87) Date publication PCT/PCT Publication Date: 1998/06/11
(45) Date de délivrance/Issue Date: 2007/02/06
(85) Entrée phase nationale/National Entry: 1999/06/04
(86) N° demande PCT/PCT Application No.: US 1997/022063
(87) N° publication PCT/PCT Publication No.: 1998/024396
(30) Priorité/Priority: 1996/12/06 (US08/764,104)


(51) Cl.Int./Int.Cl. *A61K 31/365* (2006.01),
A61K 31/35 (2006.01), *A61K 31/366* (2006.01),
A61P 25/00 (2006.01), *A61P 29/00* (2006.01)

(72) Inventeurs/Inventors:
PIOMELLI, DANIELE, US;
BELTRAMO, MASSIMILIANO, US

(73) Propriétaire/Owner:
NEUROSCIENCES RESEARCH FOUNDATION, INC.,
US

(74) Agent: DEETH WILLIAMS WALL LLP

(54) Titre : METHODES POUR TRAITER LES MALADIES MENTALES, L'INFLAMMATION ET LA DOULEUR
(54) Title: METHODS OF TREATING MENTAL DISEASES, INFLAMMATION AND PAIN



(57) **Abrégé/Abstract:**

Methods are disclosed for treating or preventing disorders such as mental diseases, inflammation and pain by inhibiting the enzyme anandamide amidohydrolase. A therapeutically effective level of an anandamide amidohydrolase inhibitor is administered such as a therapeutically effective level of a haloenol lactone. Preferably, the haloenol lactone is of formula (I) wherein R is hydrogen, R₁ is a halogen, and R₂ is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, derivatives of said haloenol lactones, and mixtures thereof. The haloenol lactone, E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one, is most preferred.



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/35	A3	(11) International Publication Number: WO 98/24396 (43) International Publication Date: 11 June 1998 (11.06.98)		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> (21) International Application Number: PCT/US97/22063 (22) International Filing Date: 25 November 1997 (25.11.97) (30) Priority Data: 08/764,104 6 December 1996 (06.12.96) US (71) Applicant: NEUROSCIENCES RESEARCH FOUNDATION, INC. [US/US]; 10640 John Jay Hopkins Drive, San Diego, CA 92121 (US). (72) Inventors: PIOMELLI, Daniele; 4992 Academy Street, San Diego, CA 92109 (US). BELTRAMO, Massimiliano; Apartment 2609, 7425 Charmant Drive, San Diego, CA 92112 (US). (74) Agent: DUNCAN, Margaret, M.; McDermott, Will & Emery, Suite 4400, 227 W. Monroe Street, Chicago, IL 60606-5096 (US). </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 27 August 1998 (27.08.98) </td> </tr> </table>			(21) International Application Number: PCT/US97/22063 (22) International Filing Date: 25 November 1997 (25.11.97) (30) Priority Data: 08/764,104 6 December 1996 (06.12.96) US (71) Applicant: NEUROSCIENCES RESEARCH FOUNDATION, INC. [US/US]; 10640 John Jay Hopkins Drive, San Diego, CA 92121 (US). (72) Inventors: PIOMELLI, Daniele; 4992 Academy Street, San Diego, CA 92109 (US). BELTRAMO, Massimiliano; Apartment 2609, 7425 Charmant Drive, San Diego, CA 92112 (US). (74) Agent: DUNCAN, Margaret, M.; McDermott, Will & Emery, Suite 4400, 227 W. Monroe Street, Chicago, IL 60606-5096 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 27 August 1998 (27.08.98)
(21) International Application Number: PCT/US97/22063 (22) International Filing Date: 25 November 1997 (25.11.97) (30) Priority Data: 08/764,104 6 December 1996 (06.12.96) US (71) Applicant: NEUROSCIENCES RESEARCH FOUNDATION, INC. [US/US]; 10640 John Jay Hopkins Drive, San Diego, CA 92121 (US). (72) Inventors: PIOMELLI, Daniele; 4992 Academy Street, San Diego, CA 92109 (US). BELTRAMO, Massimiliano; Apartment 2609, 7425 Charmant Drive, San Diego, CA 92112 (US). (74) Agent: DUNCAN, Margaret, M.; McDermott, Will & Emery, Suite 4400, 227 W. Monroe Street, Chicago, IL 60606-5096 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 27 August 1998 (27.08.98)			
(54) Title: METHODS OF TREATING MENTAL DISEASES, INFLAMMATION AND PAIN				
<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> $\begin{array}{c} \text{R} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{R}_1 \end{array}$ </div> <div style="text-align: center;"> $\begin{array}{c} \text{CH}_2 - \text{CH}_2 \\ \\ \text{O} \end{array}$ </div> <div style="text-align: center;"> $\begin{array}{c} \text{C} \\ \diagup \\ \text{R}_2 \end{array}$ </div> <div style="text-align: center;"> $\begin{array}{c} \text{O} \\ \end{array}$ </div> <div style="text-align: center;"> (1) </div> </div>				
(57) Abstract <p>Methods are disclosed for treating or preventing disorders such as mental diseases, inflammation and pain by inhibiting the enzyme anandamide amidohydrolase. A therapeutically effective level of an anandamide amidohydrolase inhibitor is administered such as a therapeutically effective level of a haloenol lactone. Preferably, the haloenol lactone is of formula (I) wherein R is hydrogen, R₁ is a halogen, and R₂ is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, derivatives of said haloenol lactones, and mixtures thereof. The haloenol lactone, E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one, is most preferred.</p>				

METHODS OF TREATING MENTAL DISEASES, INFLAMMATION AND PAINFIELD OF THE INVENTION

5 The invention relates to methods and compositions for treating disorders such as mental diseases, inflammation and pain. More particularly, the invention relates to methods for treating such disorders by administering a therapeutically effective level of an anandamide amidohydrolase inhibitor.


10 BACKGROUND OF THE INVENTION

Anandamide (N-arachidonoyl ethanolamine) is thought to act as an endogenous cannabinoid neurotransmitter in vertebrate nervous systems. It binds to and activates cannabinoid receptors and simulates many distinctive effects typical of plant-derived or synthetic cannabinoid drugs.

15 Biochemical evidence indicates that anandamide is produced in and released from neurons in an activity-dependent manner. Further, as expected of a signalling molecule, anandamide is short-lived: its life-span is limited by uptake into neural cells and by enzymatic hydrolysis. Anandamide hydrolysis is catalyzed by the enzyme anandamide amidohydrolase, which converts anandamide to yield two inactive metabolites, arachidonate and ethanolamine. This reaction is illustrated by the following:

WO 98/24396


PCT/US97/22063



Anandamide amidohydrolase is likely to play an
 5 important role in the physiological degradation of anandamide.
 Three lines of evidence support this possibility. First,
 anandamide amidohydrolase is highly selective. Second,
 anandamide amidohydrolase is discretely distributed in the
 central nervous system, where its localization parallels that of
 10 cannabinoid receptors. Third, a protease inhibitor that blocks
 anandamide amidohydrolase non-selectively,
 phenylmethanesulphonylfluoride, extends the actions of anandamide.

Therefore, inhibition of anandamide amidohydrolase to
 increase the accumulation of anandamide at its sites of action is
 15 desirable as a potential therapeutic approach for the treatment
 or prevention of disorders such as mental diseases, inflammation
 and pain, including treatment or prevention of schizophrenia,
 mood disorders, anorexia, multiple sclerosis, spasticity and
 glaucoma. Despite these potential applications, no potent and
 20 selective inhibitors of anandamide amidohydrolase have been
 identified as yet.

The anandamide amidohydrolase inhibitors useful in the
 present invention comprise haloenol lactones. The preferred
 haloenol lactones are compounds of the formula:




25

WO 98/24396

PCT/US97/22063


wherein R is hydrogen, R₁ is a halogen, and R₂ is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals. A most preferred haloenol lactone is E-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one which has the following formula:




The synthesis of this compound and the identification of its ability to inhibit an enzyme which is unrelated to anandamide amidohydrolase, i.e., the cardiac calcium-independent phospholipase A₂, have been described in the following patents and publications: Hazen, et al., J. Biol. Chem. 266, 7227-7232 (1991); Weiss, et al., U.S. Patent No. 5,208,244; and Balsinde, et al., Proc. Natl. Acad. Sci. U.S.A. 92, 8527-8531 (1995).

SUMMARY OF THE INVENTION

The invention comprises methods of treating or preventing disorders such as mental diseases, inflammation and pain, including schizophrenia, mood disorders, anorexia, multiple sclerosis, spasticity and glaucoma by administering a therapeutically effective level of an anandamide amidohydrolase inhibitor. The preferred anandamide amidohydrolase inhibitors comprise haloenol lactones. The preferred haloenol lactones are compounds of the formula:



The present invention further comprises methods of inhibiting anandamide amidohydrolase by administering a therapeutically effective amount of a haloenol lactone. The preferred haloenol lactones are compounds of the formula:



The invention further comprises pharmaceutical compositions comprising anandamide amidohydrolase inhibitors for treating mental diseases, inflammation and pain, such as schizophrenia, mood disorders, anorexia, multiple sclerosis, spasticity and glaucoma. The preferred compositions comprise a

WO 98/24396

PCT/US97/22063

haloenol lactone at a therapeutically effective level to inhibit anandamide amidohydrolase.

DESCRIPTION OF THE DRAWINGS


5 FIGURE 1 is a graph showing a comparison of the effects of a haloenol lactone of the invention on anandamide amidohydrolase activities from rat brain and rat liver;

10 FIGURES 2A and 2B are graphs showing measurements of the levels of radiolabeled arachidonic acid accumulated in the presence of various concentrations of a haloenol lactone of the invention (Fig. 2A), or levels of phospholipids containing radiolabeled arachidonic acid (Fig. 2B); and

15 FIGURE 3 is a graph showing that intracellular levels of radiolabeled anandamide were greatly increased in the presence of a haloenol lactone of the invention.

DETAILED DESCRIPTION OF THE INVENTION

20 The preferred anandamide amidohydrolase inhibitors of the invention are haloenol lactones. The preferred haloenol lactones are compounds of the general formula:



25 wherein R is hydrogen, R₁ is a halogen, and R₂ is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, and derivatives and mixtures thereof. The preferred haloenol

WO 98/24396

PCT/US97/22063

lactones useful in the methods and compositions of the invention include E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one, derivatives of this compound, and mixtures thereof.

Inhibition of anandamide amidohydrolase causes the accumulation of endogenously produced anandamide. Endogenous anandamide, in turn, activates cannabinoid receptors, resulting in therapeutically favorable effects that include mood elevation, appetite stimulation, relief of pain and inflammation, and symptomatic relief in diseases such as multiple sclerosis and glaucoma.

The following examples illustrate the anandamide amidohydrolase inhibitors of the invention.

Example 1

Anandamide amidohydrolase assay

An assay was developed which demonstrated inhibition of rat brain anandamide amidohydrolase by E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one. This assay consisted of determining the amount of radiolabeled arachidonic acid liberated from radiolabeled anandamide by rat brain anandamide amidohydrolase in the presence of various concentrations of E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one. This assay was also used to show that E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one is more effective on brain tissue anandamide amidohydrolase

WO 98/24396

PCT/US97/22063

activity, by examining its effect on rat liver anandamide amidohydrolase.

Anandamide amidohydrolase was measured in rat brain or rat liver microsome fractions. The fractions (0.1 mg of protein) were prepared following the protocols of Desarnaud et al., J. Biol. Chem. 270, 6030-6035 (1995), and were incubated in 50 mM Tris-Cl (pH 7.4) at 37°C, in the presence of radiolabeled anandamide obtained from New England Nuclear, Wilmington, DE, 221 Ci/mmol), plus various concentrations of test inhibitor (0.1-100 μ M). After 10 min. of incubation, the reactions were stopped with cold methanol, the radiolabeled lipids extracted with chloroform, and the organic phases brought to dryness under a stream of N₂ gas. The radioactive products were then fractionated by thin-layer chromatography (solvent system: chloroform/methanol/ammonia, 90:10:1 vol/vol/vol), collected by scraping appropriate areas of the chromatography plate, and quantified by liquid scintillation counting.

The effects of E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one on anandamide amidohydrolases from rat brain or liver are shown in Figure 1. This compound is potent in inhibiting brain anandamide amidohydrolase. The concentration of E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one which decreases the enzyme activity to 50% of the activity measured in the absence of the compound (defined as IC₅₀), was 0.7 μ M.

WO 98/24396

PCT/US97/22063

Underscoring the tissue differences of this inhibitory effect, inhibition of the liver enzyme was achieved at concentrations of E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one that were more than 100-fold higher than in brain ($IC_{50}=97 \mu M$).

Pharmaceutical compositions comprising the haloenol lactones of the invention can be administered utilizing an effective inhibitory amount of the compound(s). This amount can range from about 1 nM to 0.1 mM, preferably from about 1 μM to about 50 μM . A most preferred effective amount is about 10 μM . Such compositions can be prepared with acceptable diluents and/or carriers, as described, for example, in Remington's Pharmaceutical Sciences, Arthur Osol, Ed., 16th Ed., 1980, Mack Publishing Company.

Example 2

Assay in cultures of cortical astrocytes

An additional assay demonstrated inhibition of anandamide amidohydrolase in intact neural cells. This assay consisted of determining the amount of radiolabeled arachidonic acid produced, when cultures of rat cortical astrocytes were incubated in the presence of radiolabeled anandamide.

Cultures of rat cortical astrocytes, essentially free of neurons, were prepared following the standard procedures described in Cadas et al., J. Neurosci. 16, 3934-3942 (1996), and used after 3 weeks in culture. The cultures were incubated in

WO 98/24396

PCT/US97/22063

Krebs Tris solution (pH 7.4) at 37°C, in the presence of radiolabeled anandamide plus various concentrations of E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one (0.1-100 μ M). After 20 min. of incubation, the reactions were stopped with cold methanol, and the cells were scraped from the culture dishes and subjected to chloroform extraction. The organic phases were dried, and analyzed as follows. To measure radiolabeled anandamide and arachidonic acid, the organic extracts were fractionated by silica gel G column chromatography, as described in Fontana et al., Prostaglandins Leukotrienes Essential Fatty Acids 53, 301-308 (1995). Radiolabeled anandamide and arachidonic acid were eluted from the column with a solvent system of chloroform/methanol (9:1, vol/vol), and further purified by thin-layer chromatography (solvent system of chloroform/methanol/ammonia, 80:20:1, vol/vol/vol). To measure radiolabeled phospholipids, which were formed in intact cells from the enzymatic esterification of radiolabeled arachidonic acid, the organic extracts were fractionated by thin-layer chromatography (solvent system of chloroform/methanol/ammonia/water, 65:25:4:1, vol/vol/vol/vol).

E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one is potent in inhibiting the anandamide amidohydrolase of intact astrocytes (IC_{50} = 0.5 μ M). This can be shown either by measuring the levels of radiolabeled arachidonic acid accumulated in the presence of various concentrations of the inhibitor (Fig. 2A), or by measuring the levels of phospholipids

WO 98/24396


PCT/US97/22063

containing radiolabeled arachidonic acid (Fig. 2B). By contrast, E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one does not inhibit the uptake of radiolabeled anandamide. This is indicated by the fact that the intracellular levels of radiolabeled anandamide were greatly increased in the presence of this compound, which would not be expected if the uptake were inhibited (Fig. 3).

The embodiments of the invention disclosed herein have been discussed for the purpose of familiarizing the reader with novel aspects of the invention. Although preferred embodiments of the invention have been shown and described, many changes, modifications, and substitutions may be made by one having skill in the art without necessarily departing from the spirit and scope of the invention.

Claims


1. The use of a therapeutically effective amount of a haloenol lactone, the haloenol lactone comprising a compound of the formula:



wherein R is hydrogen, R₁ is a halogen, and R₂ is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, and mixtures thereof, in the manufacture of a medicament to inhibit anandamide amidohydrolase.

2. The use of a therapeutically effective amount of a haloenol lactone in the manufacture of a medicament to inhibit anandamide amidohydrolase, wherein said haloenol lactone comprises E-6 - (bromomethylene) tetrahydro - 3 - (1 - naphthalenyl) - 2H -pyrane - 2 - one.


3. The use of a therapeutically effective level of an anandamide amidohydrolase inhibitor comprising a haloenol lactone, the haloenol lactone comprising a compound of the formula:



wherein R is hydrogen, R₁ is a halogen, and R₂ is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, and mixtures thereof, in the manufacture of a medicament for treating mental disease, inflammation or pain.

4. The use of a therapeutically effective amount of a haloenol lactone in the manufacture of a medicament for treating mental disease, inflammation or pain, wherein the haloenol lactone comprises E-6 - (bromomethylene) tetrahydro - 3 - (1 - naphthalenyl) - 2H - pyrane - 2 - one.

5. A composition for treating mental disease, inflammation or pain comprising a therapeutically effective level of a haloenol lactone sufficient to inhibit anandamide amidohydrolase, the haloenol lactone comprising a compound of the formula:



wherein R is hydrogen, R₁ is a halogen, and R₂ is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, and a pharmaceutically acceptable carrier, and mixtures thereof.

6. A composition for treating mental disease, inflammation or pain comprising a therapeutically effective level of a haloenol lactone sufficient to inhibit anandamide amidohydrolase, wherein the haloenol lactone comprises E-6 – (bromomethylene) tetrahydro – 3 – (1 – naphthalenyl) – 2H-pyrane– 2 – one.
7. The use according to claim 3 or 4, wherein the mental disease comprises schizophrenia, a mood disorder, or anorexia.
8. The composition according to claim 5 or 6, wherein the mental disease comprises schizophrenia, a mood disorder, or anorexia.

1/3




Figure 1

2/3




Figure 2A




Figure 2 B

3/3




Figure 3

